The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Investment in Research & Development remained at c. .

Dermatology 52

Dermatology Sales Marketing Production 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

AUGUST 3, 2021

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities.

Sales 52

Sales Production Antibody Development 52

Pharma Marketing Network

OCTOBER 27, 2020

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine. And so you’re involved in these companies, how does that play into your overall role as a thought leader in the healthcare space?

Insulin 52

Insulin Marketing Doctor Doctors 52

Pharma Marketing Network

OCTOBER 27, 2020

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine. And so you’re involved in these companies, how does that play into your overall role as a thought leader in the healthcare space?

Insulin 52

Insulin Doctor Doctors Marketing 52

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 17, 2021

An experienced leader in drug development who has led and grown Lilly’s oncology business over the past several years, White will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.

Medicine 52

Medicine Dermatology Production Development 52